Graciela S. Alarcón

Nov 26, 2024 | the-rheumatologist.org | Graciela S. Alarcón

WASHINGTON, D.C.—Despite significant advances that have taken place over the past several years, systemic lupus erythematosus (SLE) still presents great challenges to rheumatologists, given its unpredictable clinical course and the eventual consequences the disease itself and the complexity of its treatments impose on individual patients, their families and society as a whole.

Nov 1, 2024 | jrheum.org | Graciela S. Alarcón |Laurent Arnaud |Guillermo Javier Pons-Estel |Romina Estefanía Nieto

The article by Tani et al, “Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study,”1 evaluates the efficacy of anifrolumab (ANI) in patients with systemic lupus erythematosus (SLE) who failed to respond to other treatments, including biologics. There are many unmet needs in the treatment of SLE.